Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360044 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Inhaled Cannabis for Acute Migraine Treatment
A Phase 2 study of Migraine and Cannabis, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT04360044: Completed Phase 2 study of Migraine and Cannabis, sponsored by University of California, San Diego.
NCT04360044 is a Phase 2 study of Migraine and Cannabis that has completed, run by University of California, San Diego. The registered enrollment target is 92 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04360044, a Phase 2 study of Migraine and Cannabis, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
Primary Outcome
Dichotomous endpoint of pain reduction defined as reduction from moderate/severe pain to mild/no pain
Interventions
- DRUG THC ~5%
- DRUG CBD ~12%
- DRUG THC ~5% and CBD ~12%
- DRUG Sham Cannabis
Study Locations (1)
California
- Center for Pain Medicine, UC San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 2 |
What the finished NCT04360044 record still lists
NCT04360044 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Migraine appearing as the primary indexed condition, and to 4 interventions - of which THC ~5% is the first listed.
NCT04360044 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04360044 about?
NCT04360044 is a clinical study titled "Efficacy of Inhaled Cannabis for Acute Migraine Treatment". This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.
What is the current status of trial NCT04360044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2020-11-20. Estimated completion is 2023-02-23.
What conditions does trial NCT04360044 study?
This clinical trial studies the following conditions: Migraine, Cannabis, THC, CBD.
What interventions are being tested in trial NCT04360044?
The interventions under investigation include: THC ~5% (DRUG), CBD ~12% (DRUG), THC ~5% and CBD ~12% (DRUG), Sham Cannabis (DRUG).
Who is sponsoring clinical trial NCT04360044?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04360044 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04360044's enrollment target sits among peer trials
92 63rd of 102 higher than 40 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI